Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-LTR long-term rollover study of povorcitinib
2024-520107-12-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of povorcitinib in hidradenitis suppurativa (HS), prurigo nodularis (PN) and Vitiligo, sponsored by Incyte. Primary endpoint: Treatment-emergent adverse events. Planned start Sep 2025; status: authorised.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)prurigo nodularis (PN)Vitiligo
Beyond the preview
Go deeper on 2024-520107-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520107-12-00.